Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 5, 2009, Pages 715-722

  Wang, Zheng ^a   Zhou, Jian ^a   Fan, Jia ^a   Tan, Chang Jun ^a   Qiu, Shuang Jian ^a   Yu, Yao ^a   Huang, Xiao Wu ^a   Tang, Zhao You ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; HIF 1 a protein; Immunosuppression; Liver transplantation; Neoplasm metastasis; Sirolimus; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; RAPAMYCIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ACTINS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; FIBROBLAST GROWTH FACTOR 2; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RNA, MESSENGER; SIROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 63549114458     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0506-z     Document Type: Article

References (29)

1. C Blancher JW Moore N Robertson AL Harris 2001 Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxiainducible factor (HIF)-1 alpha, HIF-2 alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway Cancer Res 61 7349 7355
2. DJ Boffa F Luan D Thomas H Yang VK Sharma M Lagman 2004 Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer Clin Cancer Res 10 293 300 10.1158/1078-0432.CCR-0629-3
3. G Breier S Blum J Peli M Groot C Wild W Risau 2002 Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis Int J Cancer 97 142 148 10.1002/ijc.1599
4. B Burke N Tang KP Corke D Tazzyman K Ameri M Wells 2002 Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxiaregulated cancer gene therapy J Pathol 196 204 212 10.1002/path.1029
5. S Chan ME Scheulen S Johnston K Mross F Cardoso C Dittrich 2005 Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer J Clin Oncol 23 5314 5322 10.1200/JCO.2005.66.130
6. K Clarke K Smith WJ Gullick AL Harris 2001 Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway Br J Cancer 84 1322 1399 10.1054/bjoc.2001.1805
7. HB El-Serag AC Mason 1999 Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 745 750 10.1056/NEJM199903113401001
8. CE Freise L Ferrell T Liu NL Ascher JP Roberts 1999 Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma Transplantation 67 510 513 10.1097/00007890-199902270- 00003
9. M Guba P von Breitenbuch M Steinbauer G Koehl S Flegel M Hornung 2002 Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 128 135 10.1038/nm0202-128
10. DA Hale R Gottschalk T Fukuzaki ML Wood T Maki AP Monaco 1997 Superiority of sirolimus (rapamycin) over cyclosporine in augmenting allograft and xenograft survival in mice treated with antilymphocyte serum and donor-specific bone marrow Transplantation 63 359 364 10.1097/00007890-199702150-00005
11. M Hojo T Morimoto M Maluccio T Asano K Morimoto M Lagman 1999 Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 530 534 10.1038/17401
12. G Hudes M Carducci P Tomczak J Dutcher R Figlin A Kapoor Global ARCC Trial 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 10.1056/NEJMoa066838
13. CC Hudson M Liu GG Chiang DM Otterness DC Loomis F Kaper 2002 Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin Mol Cell Biol 22 7004 7014 10.1128/MCB.22.20.7004-7014.2002
14. RK Jain N Safabakhsh A Sckell Y Chen P Jiang L Benjamin 1998 Endothelial cell death, angiogenesis, and microvascular function after castration in an androgendependent tumor: role of vascular endothelial growth factor Proc Natl Acad Sci USA 95 10820 10825 10.1073/pnas.95.18.10820
15. NM Kneteman J Oberholzer M Al Saghier GA Meeberg M Blitz MM Ma 2004 Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma Liver Transpl 10 1301 1311 10.1002/lt.20237
16. FL Luan M Hojo M Maluccio K Yamaji M Suthanthiran 2002 Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy Transplantation 73 1565 1572 10.1097/00007890-200205270-00008
17. K Mahalati BD Kahan 2001 Clinical pharmacokinetics of sirolimus Clin Pharmacokinet 40 573 585 10.2165/00003088-200140080-00002
18. KM Olthoff 1998 Surgical options for hepatocellular carcinoma: resection and transplantation Liver Transpl Surg 4 S98 S104
19. WK Rathmell TM Wright BI Rini 2005 Molecularly targeted therapy in renal cell carcinoma Expert Rev Anticancer Ther 5 1031 1040 10.1586/14737140.5.6.1031
20. D Semela AC Piguet M Kolev K Schmitter R Hlushchuk V Djonov 2007 Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma J Hepatol 46 840 848 10.1016/j.jhep.2006.11.021
21. FX Sun ZY Tang KD Liu Q Xue DM Gao YQ Yu 1996 Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues Int J Cancer 66 239 243 10.1002/(SICI)1097-0215(19960410)66:2<239::AID-IJC17>3.0.CO;2-7
22. MB Thomas AX Zhu 2005 Hepatocellular carcinoma: the need for progress J Clin Oncol 23 2892 2899 10.1200/JCO.2005.03.196
23. C Toso GA Meeberg DL Bigam 2007 De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects Transplantation 83 1162 1168 10.1097/01.tp.0000262607.95372.e0
24. M Vivarelli A Cucchetti F Piscaglia G La Barba L Bolondi A Cavallari 2005 Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression Liver Transpl 11 497 503 10.1002/lt.20391
25. MW Wiedmann K Caca 2005 Molecularly targeted therapy for gastrointestinal cancer Curr Cancer Drug Targets 5 171 193 10.2174/1568009053765771
26. R Yang FJ Rescorla CR Reilly PR Faught NT Sanghvi L Lumeng 1992 A reproducible rat liver cancer model for experimental therapy: introducing a technique of intrahepatic tumor implantation J Surg Res 52 193 198 10.1016/0022-4804(92)90072-8
27. JF Zhang JJ Liu MQ Lu CJ Cai Y Yang H Li 2007 Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro Transpl Immunol 17 162 168 10.1016/j.trim.2006.12.003
28. L Zhang JR Conejo-Garcia N Yang W Huang A Mohamed-Hadley W Yao 2002 Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells Biochem Biophys Res Commun 292 860 868 10.1006/bbrc.2002.6710
29. MA Zimmerman JF Trotter M Wachs T Bak J Campsen A Skibba 2008 Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma Liver Transpl 14 633 638 10.1002/lt.21420